Paper Details

  1. Home
  2. Paper Details

Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.

Author: BrownP, GibsonJ A, GreenJ R, KerrG D, RowlinsonA, SwanC H, SwarbrickE T, ThorntonP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Balsalazide was found to be effective in maintaining remission in patients with ulcerative colitis. Remission rates were 77% for the 3 g/day dose and 68% for the 6 g/day dose after 12 months. The study found no significant difference between the two doses in terms of remission rates, but a higher dose may be more effective for some patients.
Paper Details　
Original Abstract of the Article :
In a four-centre prospective double-blind trial, 108 patients with ulcerative colitis in remission were randomized to receive balsalazide in doses of 3 g or 6 g/day for 12 months. The patients were assessed at 3-monthly intervals clinically, sigmoidoscopically and with routine haematology and bioche...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2036.1992.tb00578.x

データ提供：米国国立医学図書館（NLM）

Balsalazide: A Steady Hand in Maintaining Ulcerative Colitis Remission

Managing [ulcerative colitis] is a delicate dance, requiring effective [maintenance therapies] to keep symptoms at bay. This research investigates the [efficacy] of [balsalazide] in [maintaining remission] in patients with [ulcerative colitis]. The authors conducted a [prospective, double-blind trial] comparing two doses of [balsalazide] over a [12-month period]. Their findings demonstrate that [balsalazide] is [highly effective] in [maintaining remission] and is [well tolerated] by patients, with a [similar efficacy] observed for both [dosages] studied.

Balsalazide: A Steady Hand in Maintaining Ulcerative Colitis Remission

The study provides reassuring evidence for the [effectiveness] of [balsalazide] in [managing ulcerative colitis]. The authors found no significant difference in [remission rates] between the [two doses] tested, suggesting that [balsalazide] can be effectively used to [maintain remission] in patients with [ulcerative colitis], regardless of the [dosage] chosen. This finding provides valuable information for clinicians in [selecting appropriate treatment] for their patients.

Balsalazide: A Steady Hand in Maintaining Ulcerative Colitis Remission

This research offers hope for patients with [ulcerative colitis], demonstrating that [balsalazide] can be a reliable tool for [maintaining remission] and improving [quality of life]. The study's findings highlight the importance of [personalized treatment] and the need to [carefully consider] the [individual needs] of patients when selecting a [maintenance therapy] for [ulcerative colitis].

Dr. Camel's Conclusion

Like a camel traversing a sandy expanse, patients with [ulcerative colitis] need a reliable companion to navigate the challenges of their condition. This study suggests that [balsalazide] can serve as that dependable companion, helping to maintain [remission] and improve [quality of life]. The findings are a reminder that [personalized medicine] is crucial in [ulcerative colitis management], ensuring that patients receive the most effective and well-tolerated treatment options.

Date :
  1. Date Completed 1992-12-18
  2. Date Revised 2019-08-27
Further Info :

Pubmed ID

1420754

DOI: Digital Object Identifier

10.1111/j.1365-2036.1992.tb00578.x

Related Literature

Article Analysis
・Effects of balsalazide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.